Today: 20 May 2026
Browse Category

NASDAQ:ARWR 25 November 2025 - 9 February 2026

Arrowhead Pharmaceuticals stock swings as S&P MidCap 400 move lands and Goldman flags 2026 catalysts (ARWR)

Arrowhead Pharmaceuticals stock swings as S&P MidCap 400 move lands and Goldman flags 2026 catalysts (ARWR)

Arrowhead Pharmaceuticals shares fell 0.7% to $64.10 in afternoon trading Monday after moving from the S&P SmallCap 600 to the S&P MidCap 400. The stock saw heavy volume and a wide intraday range. Goldman Sachs maintained a Neutral rating and $85 target, citing key 2026 pipeline data and competition from Ionis Pharmaceuticals. Arrowhead recently reported Q1 revenue of $264 million and 22 cents EPS.
9 February 2026
··
Arrowhead Pharmaceuticals stock slides despite Health Canada approval of Redemplo — what investors watch next

Arrowhead Pharmaceuticals stock slides despite Health Canada approval of Redemplo — what investors watch next

Arrowhead Pharmaceuticals shares fell 6.9% to $63.11 Monday after Health Canada approved Redemplo, its triglyceride-lowering drug for familial chylomicronemia syndrome. The stock dropped despite the clearance, tracking weakness across biotech stocks. Investors now await Arrowhead’s obesity data webinar on Jan. 6 and its J.P. Morgan conference presentation Jan. 12.
5 January 2026
···
Arrowhead Pharmaceuticals stock slides today as biotech dips; ARWR investors eye January obesity data

Arrowhead Pharmaceuticals stock slides today as biotech dips; ARWR investors eye January obesity data

Arrowhead Pharmaceuticals shares fell 3.6% to $67.09 by early afternoon Tuesday, outpacing declines in biotech peers as traders positioned ahead of key January updates. The drop followed recent volatility after FDA approval of REDEMPLO, the company’s first commercial drug for familial chylomicronemia syndrome. Arrowhead plans to release interim obesity-program data and present at the J.P. Morgan Healthcare Conference in early January.
30 December 2025
··
Arrowhead Pharmaceuticals (ARWR) Stock Drops on Dec. 16, 2025: Latest News, Analyst Forecasts, and What Investors Are Watching

Arrowhead Pharmaceuticals (ARWR) Stock Drops on Dec. 16, 2025: Latest News, Analyst Forecasts, and What Investors Are Watching

Arrowhead Pharmaceuticals shares fell about 9% Tuesday, trading near $62 after touching an intraday low of $59.76. The decline follows a recent surge to a 52-week high after FDA approval of its first drug, REDEMPLO, and an FDA Breakthrough Therapy designation. No single negative catalyst was cited; analysts pointed to profit-taking and volatility after recent gains. Arrowhead also disclosed routine equity grants for new hires.
16 December 2025
··
Arrowhead Pharmaceuticals (ARWR) Stock Near 52‑Week High After FDA Approval and New Alzheimer’s Trial: Latest News & Forecasts as of December 11, 2025

Arrowhead Pharmaceuticals (ARWR) Stock Near 52‑Week High After FDA Approval and New Alzheimer’s Trial: Latest News & Forecasts as of December 11, 2025

Arrowhead Pharmaceuticals shares surged to a new 52-week high above $72 on December 11 after the FDA approved its first drug, Redemplo, for familial chylomicronemia syndrome. The stock has climbed from the low-$40s to around $70 in a month, pushing market value to $9.6 billion, up over 300% year-over-year. The company also received an FDA Breakthrough Therapy designation and launched its first Alzheimer’s trial.
11 December 2025
··
Arrowhead Pharmaceuticals (ARWR) Stock Soars on First FDA Approval, Novartis Deal and New Alzheimer’s Trial

Arrowhead Pharmaceuticals (ARWR) Stock Soars on First FDA Approval, Novartis Deal and New Alzheimer’s Trial

Arrowhead Pharmaceuticals stock surged to a 52-week high of $71.5 on December 8, 2025, after securing its first FDA approval for REDEMPLO and announcing a major Novartis licensing deal. Shares traded around $69 on December 9, up over 260% year-to-date, with market value near $9.5 billion. Trading volume more than doubled typical levels. The company also began dosing in an Alzheimer’s trial.
9 December 2025
··
Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins

Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins

Arrowhead Pharmaceuticals shares jumped 14–15% intraday on 8 December 2025, reaching a 52-week high near $69 after dosing the first subjects in its Alzheimer’s trial ARO-MAPT. The stock has returned about 270% year-to-date, with a market cap around $9–9.6 billion. The Phase 1/2a trial targets tau protein using Arrowhead’s RNAi platform. Liquidity ratios stand near 4.8, with beta between 1.3 and 1.5.
8 December 2025
·
SRPT Stock Today, November 25, 2025: Sarepta Rises on SRP‑1003 Progress While Elevidys Risks Still Loom

SRPT Stock Today, November 25, 2025: Sarepta Rises on SRP‑1003 Progress While Elevidys Risks Still Loom

Sarepta shares closed Monday at $18.90, up 6.9%, after a positive safety update for its experimental RNA therapy SRP‑1003. The company hit an enrollment milestone in its DM1 trial, triggering a $200 million payment to Arrowhead Pharmaceuticals. SRPT stock remains down about 85% year-to-date following setbacks with its gene therapy Elevidys.
25 November 2025
····

Stock Market Today

  • Parle Industries Stock Soars On PM Modi's Melody Diplomacy; Unrelated To Parle Products
    May 20, 2026, 5:12 AM EDT. Shares of Parle Industries surged to the upper circuit limit following Prime Minister Narendra Modi's references to 'melody diplomacy.' Notably, Parle Industries is distinct from Parle Products, the maker of popular snack brands like Parle-G, Monaco, Hide & Seek, and Mango Bite. Investors should note the companies are unrelated entities, despite similar names. The stock's sharp rise underscores market sensitivity to geopolitical and cultural developments, even when corporate links are not direct.

Latest articles

Klaviyo Stock Holds Near Lows; Direction Awaits Key Decision

Klaviyo Stock Holds Near Lows; Direction Awaits Key Decision

20 May 2026
Klaviyo closed Tuesday at $14.70, up 0.6%, but remained near its 52-week low after a sharp post-earnings drop. A May 18 Form 144 notice signaled potential insider sales. Shares were down about 27% in the past month and 57% over the year, with a market value near $4.4 billion. First-quarter revenue rose 28% to $358 million, but growth is forecast to slow.
Chewy Shares Slide on CEO Talk of “Stretched Consumer”

Chewy Shares Slide on CEO Talk of “Stretched Consumer”

20 May 2026
Chewy Inc. shares dropped 9.1% to $19.66 Tuesday after CEO Sumit Singh warned U.S. consumers are more financially strained than earlier this year. The decline put Chewy near its 52-week low ahead of its June 10 earnings report. Singh made the comments at a J.P. Morgan conference, citing multiple data points on weaker consumer demand. Petco fell 2.9%, while BARK rose 7.5% and Amazon slipped 2.1%.
Meiwu Technology Stock Jumps Again After 97% Surge: Why WNW Is Moving Now

Meiwu Technology Stock Jumps Again After 97% Surge: Why WNW Is Moving Now

20 May 2026
Meiwu Technology shares jumped 97% to $4.75 Tuesday and rose another 12% premarket after the company raised $15.65 million in a private share sale to fund an AI skincare platform. The rally follows a 1-for-100 reverse share split in April and earlier $14 million direct offering. Meiwu warned its new platform is early-stage and faces regulatory risks.
Go toTop